Company intelligence / Profile preview

Sycamore BioPharma

West Columbia, South Carolina, United States

Ownership: Private
Development stage: Other

Overview

Sycamore BioPharma’s commercial portfolio includes CBD-based products for pain, sleep, and wellness. Preclinical natural product programs for oncology, infectious, neuropsychiatric, and addiction indications are being developed, with clinical trial preparations underway in partnership with MUSC.

Therapeutic areas: Infectious DiseasesOncologyNeurologyPsychiatry
Modalities: Small moleculeBiologicBotanical extractCannabinoidPlant-derived product
Industry: Biotech

Partnerships

Medical University of South CarolinaTextile chemistry company

Beyond the preview

Go deeper on Sycamore BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sycamore BioPharma.

Explore the full profile